Stocktoria
KIORA PHARMACEUTICALS INC KPRX
KIORA PHARMACEUTICALS INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $16.0M | $0 | — | $0 | $12,059 | $2.7M | $1.7M | $407,518 | $669,259 |
| R&D expense | $10.8M | $7.8M | $4.0M | $3.4M | $5.4M | $3.6M | $5.4M | $8.1M | $10.3M | $8.4M |
| Operating income | -$12.8M | $4.5M | -$12.6M | -$12.3M | -$14.2M | -$8.2M | — | -$10.8M | — | — |
| Interest expense | — | — | $11,132 | $8,599 | $6,851 | $4,186 | $325 | $1,040 | $1,215 | $275 |
| Income tax | -$1.3M | $2.1M | $90,319 | -$113,010 | -$192,603 | $12,055 | $95,396 | $86,045 | -$1.3M | $0 |
| Net income | -$10.8M | $3.6M | -$12.5M | -$13.6M | -$13.8M | -$8.1M | -$7.1M | -$10.8M | -$13.2M | — |
| EPS (diluted) | $-2.64 | $0.87 | $-24.25 | $-18.55 | $-57.12 | $-1.77 | — | — | — | — |
| Operating cash flow | -$10.0M | $8.6M | -$9.6M | -$10.4M | -$10.7M | -$7.3M | -$8.2M | -$10.8M | -$6.5M | -$8.4M |
| Free cash flow | -$10.1M | $8.6M | -$9.6M | -$10.4M | -$10.7M | -$7.3M | -$8.2M | -$10.9M | -$6.5M | -$8.4M |
| Cash & equivalents | $8.7M | $3.8M | $2.5M | $6.0M | $7.9M | $1.2M | $3.8M | $8.0M | $7.8M | $3.6M |
| Total assets | $24.3M | $36.5M | $13.7M | $18.7M | $20.1M | $15.2M | $10.1M | $14.3M | $14.3M | $9.7M |
| Total liabilities | $8.1M | $10.7M | $7.6M | $7.3M | $5.6M | $8.2M | $3.5M | $5.3M | $16.2M | $10.1M |
| Shareholders' equity | $16.1M | $25.8M | $6.1M | $11.4M | $14.6M | $9.7M | $6.6M | $8.9M | $7.6M | -$329,421 |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -100.0% | — | — | — | -100.0% | -99.6% | +62.5% | +305.5% | -39.1% | — |
| Net income growth | -401.4% | — | — | — | — | — | — | — | — | — |
| EPS growth | -403.4% | — | — | — | — | — | — | — | — | — |
| Free cash flow growth | -217.8% | — | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.